Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Alnylam Clinical Trial Information Line 1-877-ALNYLAM
clinicaltrials@alnylam.com


Alnylam Clinical Trial Information Line 1-877-256-9526
clinicaltrials@alnylam.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Back

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Recruiting

Open to: ALL

Age: 18.0 - N/A

London Sheffield

Medical Conditions

Alzheimer Disease

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2022 Jul 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : ALN-APP will be administered intrathecally (IT)

Intervention Arm Group : Part A: ALN-APP;Part B:;

Intervention Type : DRUG
Intervention Description : Placebo will be administered IT

Intervention Arm Group : Part A: Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Clinical Trial Site
    London
  • Clinical Trial Site
    Sheffield

Alnylam Clinical Trial Information Line 1-877-256-9526
clinicaltrials@alnylam.com


Alnylam Clinical Trial Information Line 1-877-ALNYLAM
clinicaltrials@alnylam.com



The study is sponsored by Alnylam Pharmaceuticals



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05231785
Last updated 03 February 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top